Trial · NCT02610140
Participant flow26
How many started, completed or left each group, period by period.
1 to 20 of 26
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomization and Treatment Period | STARTED | Anetumab Ravtansine (Experimental) | 166 | |
| Randomization and Treatment Period | STARTED | Vinorelbine (Active Comparator) | 82 | |
| Randomization and Treatment Period | Participants Received Treatment | Anetumab Ravtansine (Experimental) | 163 | |
| Randomization and Treatment Period | Participants Received Treatment | Vinorelbine (Active Comparator) | 72 | |
| Randomization and Treatment Period | COMPLETED | Anetumab Ravtansine (Experimental) | 0 | |
| Randomization and Treatment Period | COMPLETED | Vinorelbine (Active Comparator) | 0 | |
| Randomization and Treatment Period | NOT COMPLETED | Anetumab Ravtansine (Experimental) | 166 | |
| Randomization and Treatment Period | NOT COMPLETED | Vinorelbine (Active Comparator) | 82 | |
| Safety Follow-up | STARTED | Anetumab Ravtansine (Experimental) | 102 | |
| Safety Follow-up | STARTED | Vinorelbine (Active Comparator) | 45 | |
| Safety Follow-up | COMPLETED | Anetumab Ravtansine (Experimental) | 57 | |
| Safety Follow-up | COMPLETED | Vinorelbine (Active Comparator) | 21 | |
| Safety Follow-up | NOT COMPLETED | Anetumab Ravtansine (Experimental) | 45 | |
| Safety Follow-up | NOT COMPLETED | Vinorelbine (Active Comparator) | 24 | |
| Active Follow-up | STARTED | Anetumab Ravtansine (Experimental) | 48 | |
| Active Follow-up | STARTED | Vinorelbine (Active Comparator) | 26 | |
| Active Follow-up | COMPLETED | Anetumab Ravtansine (Experimental) | 0 | |
| Active Follow-up | COMPLETED | Vinorelbine (Active Comparator) | 0 | |
| Active Follow-up | NOT COMPLETED | Anetumab Ravtansine (Experimental) | 48 | |
| Active Follow-up | NOT COMPLETED | Vinorelbine (Active Comparator) | 26 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02610140/flow